Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T17:03:46.258Z.
Calculation as of: 2026-10-06T17:03:46.258Z.
Quote observation: 2026-10-06T17:00:47.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 310997c20848bd5012eb98bb82f11fa46ca59880ef1b58a452bebfeaa3e5ded1
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
Phathom Pharmaceuticals, Inc.
Market Cap
$537.59M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$536.81M
Operating Cash Flow Yield
3.65%
TTM Avg
3.98%
3Y Avg
3.57%
5Y Avg
3.57%
Market Cap
$537.71M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$535.96M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$539.62M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$541.49M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$543.14M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$525.68M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$525.57M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Phathom Pharmaceuticals, Inc. (PHAT) | $537.59M | N/A | N/A | N/A | N/A |
| Delcath Systems, Inc. (DCTH)vs › | $536.81M | 3.65% | 3.98% | 3.57% | 3.57% |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $537.71M | N/A | N/A | N/A | N/A |
| ProKidney Corp. (PROK)vs › | $535.96M | N/A | N/A | N/A | N/A |
| Nuvectis Pharma, Inc. (NVCT)vs › | $539.62M | N/A | N/A | N/A | N/A |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $541.49M | N/A | N/A | N/A | N/A |
| Shattuck Labs, Inc. (STTK)vs › | $543.14M | N/A | N/A | N/A | N/A |
| Monopar Therapeutics Inc. (MNPR)vs › | $525.68M | N/A | N/A | N/A | N/A |
| Immix Biopharma, Inc. (IMMX)vs › | $525.57M | N/A | N/A | N/A | N/A |
| Altimmune, Inc. (ALT)vs › | $515.36M | N/A | 536.71% | 536.71% | 536.71% |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
